AGTR1 and hypertensive disorder: Another research group focused on using antibodies to block G protein-coupled receptors (GPCRs) to alleviate hypertension, screening and modifying humanized nanobodies like AT118i4 as AT1R antagonists, offering new therapeutic avenues [73].